Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...
PMLiVE6d
LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab
LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...
Morningstar5d
Gilead Sciences Inc GILD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Yahoo Finance2d
Gilead Sciences, Inc. (GILD)
After hours: 7:59:47 p.m. EST ...
gut.bmj5d
Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets
1 Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, the Netherlands 2 Department of Experimental Internal Medicine, Academic Medical Centre, Amsterdam, the Netherlands ...